Skip to Main Content

Paper Details

Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Am J Nephrol
5
2022
AP, Ba, C3, C3 Glomerulopathy, C3 glomerulopathy, C3G, C4, C5, Danicopan, FD, Factor D, Patients, danicopan, dysregulation of the alternative pathway, factor D, kidney disease, patients, plasma sC5b-9, proteinuria, sC5b-9
Author NameAffiliation
Samir M ParikhThe Ohio State University Medical Center
Samir M ParikhThe Ohio State University Medical Center
James A Tumlin
  • 1 - 3

Datasets

Release 1.2